AI Drug Discovery Health Tech Innovation Atlas (HTIA)

Our AI Drug Discovery HTIA includes market insights and dynamics, detailed sector and sub-sector descriptions, and companies differentiated by segment (from early-stage to established). By leveraging industry knowledge, market research, and deal sourcing, our HTIA is built from the ground-up and is constantly updated based on market changes.

Preview of the AI Drug Discovery HTIA

Artificial Intelligence (AI) is revolutionizing drug discovery, with the first AI-designed drug receiving FDA Orphan Drug Designation in 2023. As detailed in our AI Drug Discovery Industry Report, AI systems have been developed for target identification, drug design, candidate screening, and even preclinical testing.

If you are interested in obtaining an unredacted version of our AI Drug Discovery HTIA, please contact us at info@brookshillpartners.com.

To explore this sector and more, visit our HTIA library.

Brooks Hill Partners is a life sciences consultancy and early-stage health tech venture capital firm that partners with passionate companies across the biopharma and healthcare landscape. Please connect with us to learn more about how we can help you today. For more information, visit https://www.brookshillpartners.com/ and follow us on LinkedIn.